Trial reportClinical interventions in aging2026
The Effective Dose of Remifentanil Combined with Remimazolam in Inhibiting Tracheal Intubation Responses in Elderly Patients: An Up-Down Dose-Finding Study.
Trial report in Clinical interventions in aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Hemodynamic instability during tracheal intubation in elderly patients poses significant perioperative risks. This study aimed to determine the effective doses (ED50/ED95) of remifentanil combined with remimazolam to suppress intubation-induced stress responses while minimizing hypotension in patients aged ≥60. Patients and Methods: In this prospective, double-blind trial, 29 elderly patients received remimazolam (0.3 mg/kg) followed by rocuronium and remifentanil (initial dose: 1 µg/kg, adjusted via Dixon's up-down method). Hemodynamic parameters (blood pressure, heart rate, systemic vascular resistance, cardiac output) and bispectral index (BIS) were recorded. Probit regression analyzed dose-response relationships. A positive hemodynamic response was defined as an increase in systolic blood pressure or heart rate exceeding 20% of the baseline value within 5 minutes after endotracheal intubation. Dixon's up-and-down method and probit regression analysis to determine the ED50 and ED95 of remifentanil combined with remimazolam to suppress intubation-induced stress responses in elderly patients. Results: The ED50 and ED95 of remifentanil were 0.85 µg/kg (95% CI: 0.80-0.90) and 0.97 µg/kg (95% CI: 0.91-1.21), respectively. Positive responders showed elevated blood pressure at 30s-1 min post-intubation ( Conclusion: In this exploratory dose-finding study, the estimated ED50 and ED95 of remifentanil for suppressing intubation-related hemodynamic responses during remimazolam-based induction were 0.85 and 0.97 μg/kg, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.